As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.